The database
Every compound, graded by what the evidence actually shows
18 profiles covering cognition, mitochondria, nerve repair, sleep and inflammation. Each one states what the research reports, what it does not, and which practice shares the mechanism.
The whole library, at a glance
Sort by evidence grade, primary use, whether human data exists, or half-life.
| Routes | Actions | |||||
|---|---|---|---|---|---|---|
| Cerebrolysin | Cognition & mood | Evidence grade: Human trials | No | Component-dependent; dosing is course-based rather than driven by half-life | Intramuscular, Subcutaneous | Compare |
| NAD+ precursors | Mitochondria & energy | Evidence grade: Human trials | Yes | Oral dosing raises NAD+ over hours; tissue effects accumulate over weeks | Oral, Subcutaneous | Compare |
| Thymosin Alpha-1 | Immune & recovery | Evidence grade: Human trials | Yes | Roughly 2 hours; immune effects persist far longer | Subcutaneous | Compare |
| Urolithin A | Mitochondria & energy | Evidence grade: Human trials | No | Extended by glucuronidation; steady state reached over days | Oral | Compare |
| DSIP | Sleep | Evidence grade: Early human data | No | Very short in plasma — around 7–15 minutes | Subcutaneous, Intranasal | Compare |
| Epitalon | Sleep | Evidence grade: Early human data | Yes | Very short in plasma; effects described as outlasting exposure | Subcutaneous, Intranasal | Compare |
| GHK-Cu | Nerve & tissue repair | Evidence grade: Early human data | Yes | Short systemically; topical action is local and sustained | Topical, Subcutaneous | Compare |
| Noopept | Cognition & mood | Evidence grade: Early human data | No | Roughly 30–60 minutes for the parent compound; the active metabolite persists longer | Oral, Intranasal | Compare |
| Selank | Cognition & mood | Evidence grade: Early human data | No | Short in plasma; behavioural effects reported for several hours | Intranasal, Subcutaneous | Compare |
| Semax | Cognition & mood | Evidence grade: Early human data | Yes | Very short in plasma (minutes); central effects reported to outlast it considerably | Intranasal, Subcutaneous | Compare |
| SS-31 | Mitochondria & energy | Evidence grade: Early human data | No | Roughly 2–4 hours in plasma; tissue mitochondrial retention is far longer | Subcutaneous | Compare |
| BPC-157 | Nerve & tissue repair | Evidence grade: Animal studies only | No | Short in plasma; reported to be unusually stable in gastric juice | Subcutaneous, Oral | Compare |
| Dihexa | Cognition & mood | Evidence grade: Animal studies only | No | Not characterised in humans | Oral, Topical | Compare |
| Humanin | Mitochondria & energy | Evidence grade: Animal studies only | Yes | Short in circulation; poorly characterised | Subcutaneous | Compare |
| KPV | Immune & recovery | Evidence grade: Animal studies only | Yes | Short; oral use targets local gut action rather than systemic exposure | Oral, Subcutaneous, Topical | Compare |
| MOTS-c | Mitochondria & energy | Evidence grade: Animal studies only | No | Short in circulation; not well characterised in humans | Subcutaneous | Compare |
| P21 | Cognition & mood | Evidence grade: Animal studies only | No | Not characterised in humans | Intranasal, Subcutaneous | Compare |
| TB-500 | Nerve & tissue repair | Evidence grade: Animal studies only | No | Longer-acting than BPC-157, which is why twice-weekly dosing is conventional | Subcutaneous, Intramuscular | Compare |
- CerebrolysinEvidence grade: Human trials
- Primary use
- Cognition & mood
- Human data
- No
- Half-life
- Component-dependent; dosing is course-based rather than driven by half-life
- NAD+ precursorsEvidence grade: Human trials
- Primary use
- Mitochondria & energy
- Human data
- Yes
- Half-life
- Oral dosing raises NAD+ over hours; tissue effects accumulate over weeks
- Thymosin Alpha-1Evidence grade: Human trials
- Primary use
- Immune & recovery
- Human data
- Yes
- Half-life
- Roughly 2 hours; immune effects persist far longer
- Urolithin AEvidence grade: Human trials
- Primary use
- Mitochondria & energy
- Human data
- No
- Half-life
- Extended by glucuronidation; steady state reached over days
- DSIPEvidence grade: Early human data
- Primary use
- Sleep
- Human data
- No
- Half-life
- Very short in plasma — around 7–15 minutes
- EpitalonEvidence grade: Early human data
- Primary use
- Sleep
- Human data
- Yes
- Half-life
- Very short in plasma; effects described as outlasting exposure
- GHK-CuEvidence grade: Early human data
- Primary use
- Nerve & tissue repair
- Human data
- Yes
- Half-life
- Short systemically; topical action is local and sustained
- NoopeptEvidence grade: Early human data
- Primary use
- Cognition & mood
- Human data
- No
- Half-life
- Roughly 30–60 minutes for the parent compound; the active metabolite persists longer
- SelankEvidence grade: Early human data
- Primary use
- Cognition & mood
- Human data
- No
- Half-life
- Short in plasma; behavioural effects reported for several hours
- SemaxEvidence grade: Early human data
- Primary use
- Cognition & mood
- Human data
- Yes
- Half-life
- Very short in plasma (minutes); central effects reported to outlast it considerably
- SS-31Evidence grade: Early human data
- Primary use
- Mitochondria & energy
- Human data
- No
- Half-life
- Roughly 2–4 hours in plasma; tissue mitochondrial retention is far longer
- BPC-157Evidence grade: Animal studies only
- Primary use
- Nerve & tissue repair
- Human data
- No
- Half-life
- Short in plasma; reported to be unusually stable in gastric juice
- DihexaEvidence grade: Animal studies only
- Primary use
- Cognition & mood
- Human data
- No
- Half-life
- Not characterised in humans
- HumaninEvidence grade: Animal studies only
- Primary use
- Mitochondria & energy
- Human data
- Yes
- Half-life
- Short in circulation; poorly characterised
- KPVEvidence grade: Animal studies only
- Primary use
- Immune & recovery
- Human data
- Yes
- Half-life
- Short; oral use targets local gut action rather than systemic exposure
- MOTS-cEvidence grade: Animal studies only
- Primary use
- Mitochondria & energy
- Human data
- No
- Half-life
- Short in circulation; not well characterised in humans
- P21Evidence grade: Animal studies only
- Primary use
- Cognition & mood
- Human data
- No
- Half-life
- Not characterised in humans
- TB-500Evidence grade: Animal studies only
- Primary use
- Nerve & tissue repair
- Human data
- No
- Half-life
- Longer-acting than BPC-157, which is why twice-weekly dosing is conventional
Cognition & mood
Cerebrolysin
Evidence grade: Human trialsCognition & mood
A peptide mixture with the largest human trial base of anything in the nootropic category — and correspondingly mixed results.
Read the profile →DSIP
Evidence grade: Early human dataSleep
A nonapeptide isolated from rabbit brain during slow-wave sleep, studied for sleep architecture and, unexpectedly, for withdrawal symptoms.
Read the profile →GHK-Cu
Evidence grade: Early human dataNerve & tissue repair
A naturally occurring copper-binding tripeptide whose plasma levels fall by roughly two-thirds between age 20 and 60.
Read the profile →Noopept
Evidence grade: Early human dataCognition & mood
A dipeptide nootropic with Russian clinical use, reported to raise both BDNF and NGF at low oral doses.
Read the profile →Selank
Evidence grade: Early human dataCognition & mood
A tuftsin-derived anxiolytic peptide studied for generalised anxiety, with benzodiazepine-like calming reported without sedation or dependence.
Read the profile →Semax
Evidence grade: Early human dataCognition & mood
A Russian-developed ACTH fragment studied for attention, stroke recovery and BDNF expression, without the hormonal activity of ACTH itself.
Read the profile →BPC-157
Evidence grade: Animal studies onlyNerve & tissue repair
A gastric-juice-derived peptide with an unusually broad animal literature on tissue repair — and a persistent absence of human trials.
Read the profile →Dihexa
Evidence grade: Animal studies onlyCognition & mood
An angiotensin IV derivative reported to be orders of magnitude more potent than BDNF at driving synapse formation — with essentially no human data.
Read the profile →Humanin
Evidence grade: Animal studies onlyMitochondria & energy
The first mitochondrial-derived peptide discovered, identified through its ability to protect neurons from amyloid-beta toxicity.
Read the profile →P21
Evidence grade: Animal studies onlyCognition & mood
A CNTF-derived fragment studied for neurogenesis and BDNF elevation in models of Alzheimer's disease.
Read the profile →
Mitochondria & energy
NAD+ precursors
Evidence grade: Human trialsMitochondria & energy
Not peptides, but included because they are the most human-tested way to support the same mitochondrial pathway the peptides above target.
Read the profile →Urolithin A
Evidence grade: Human trialsMitochondria & energy
A gut-derived metabolite that triggers mitophagy — the clearance of damaged mitochondria — with completed human trials.
Read the profile →Epitalon
Evidence grade: Early human dataSleep
A pineal-derived tetrapeptide studied in long-running Russian cohorts for melatonin rhythm and telomerase activity.
Read the profile →SS-31
Evidence grade: Early human dataMitochondria & energy
A cardiolipin-targeting peptide that concentrates in the inner mitochondrial membrane, in human trials for primary mitochondrial disease.
Read the profile →Humanin
Evidence grade: Animal studies onlyMitochondria & energy
The first mitochondrial-derived peptide discovered, identified through its ability to protect neurons from amyloid-beta toxicity.
Read the profile →MOTS-c
Evidence grade: Animal studies onlyMitochondria & energy
A mitochondria-encoded peptide that acts as a metabolic signal to the rest of the body, studied for insulin sensitivity and exercise capacity.
Read the profile →
Nerve & tissue repair
Cerebrolysin
Evidence grade: Human trialsCognition & mood
A peptide mixture with the largest human trial base of anything in the nootropic category — and correspondingly mixed results.
Read the profile →GHK-Cu
Evidence grade: Early human dataNerve & tissue repair
A naturally occurring copper-binding tripeptide whose plasma levels fall by roughly two-thirds between age 20 and 60.
Read the profile →Semax
Evidence grade: Early human dataCognition & mood
A Russian-developed ACTH fragment studied for attention, stroke recovery and BDNF expression, without the hormonal activity of ACTH itself.
Read the profile →SS-31
Evidence grade: Early human dataMitochondria & energy
A cardiolipin-targeting peptide that concentrates in the inner mitochondrial membrane, in human trials for primary mitochondrial disease.
Read the profile →BPC-157
Evidence grade: Animal studies onlyNerve & tissue repair
A gastric-juice-derived peptide with an unusually broad animal literature on tissue repair — and a persistent absence of human trials.
Read the profile →KPV
Evidence grade: Animal studies onlyImmune & recovery
The smallest active fragment of alpha-MSH, studied as an anti-inflammatory without the pigmentation effects of the parent hormone.
Read the profile →P21
Evidence grade: Animal studies onlyCognition & mood
A CNTF-derived fragment studied for neurogenesis and BDNF elevation in models of Alzheimer's disease.
Read the profile →TB-500
Evidence grade: Animal studies onlyNerve & tissue repair
A synthetic fragment of thymosin beta-4, studied for cell migration and tissue repair — frequently paired with BPC-157 in repair protocols.
Read the profile →
Sleep
DSIP
Evidence grade: Early human dataSleep
A nonapeptide isolated from rabbit brain during slow-wave sleep, studied for sleep architecture and, unexpectedly, for withdrawal symptoms.
Read the profile →Epitalon
Evidence grade: Early human dataSleep
A pineal-derived tetrapeptide studied in long-running Russian cohorts for melatonin rhythm and telomerase activity.
Read the profile →
Immune & recovery
Thymosin Alpha-1
Evidence grade: Human trialsImmune & recovery
An immune-modulating thymic peptide approved in dozens of countries, with the most substantial regulatory footprint of anything on this site.
Read the profile →Selank
Evidence grade: Early human dataCognition & mood
A tuftsin-derived anxiolytic peptide studied for generalised anxiety, with benzodiazepine-like calming reported without sedation or dependence.
Read the profile →KPV
Evidence grade: Animal studies onlyImmune & recovery
The smallest active fragment of alpha-MSH, studied as an anti-inflammatory without the pigmentation effects of the parent hormone.
Read the profile →TB-500
Evidence grade: Animal studies onlyNerve & tissue repair
A synthetic fragment of thymosin beta-4, studied for cell migration and tissue repair — frequently paired with BPC-157 in repair protocols.
Read the profile →